Sheng-Wei Pan1,2,3, Yung-Feng Yen2,3,4,5, Jia-Yih Feng1,2,6, Pei-Hung Chuang7, Vincent Yi-Fong Su2,6,8, Yu Ru Kou9,10, Wei-Juin Su1,2, Yu-Jiun Chan3,11,12,13. 1. Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 2. Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Institute of Public Health, National Yang-Ming University, Taipei, Taiwan. 4. Section of Infectious Diseases, Taipei City Hospital, Taipei, Taiwan. 5. Department of Health Care Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. 6. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. 7. Taipei Association of Health and Welfare Data Science, Taiwan. 8. Department of Internal Medicine, Taipei City Hospital, Taipei, Taiwan. 9. Institute of Physiology, National Yang-Ming University, Taipei, Taiwan. 10. Institute of Emergency and Critical Care Medicine, National Yang-Ming University, Taipei, Taiwan. 11. Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 12. Division of Microbiology, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 13. Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan.
Abstract
It remains uncertain whether statin use is associated with the risks of tuberculosis (TB) and herpes zoster in patients with type 2 diabetes. This study aims to assess the effects of statins vs nonstatin lipid-lowering agents on the risk of these infectious diseases in patients with diabetes. METHODS: Participants in the Taiwan National Health Insurance Research Database diagnosed with type 2 diabetes in 2001-2013 were classified as statin users, nonstatin users and lipid-lowering drug-free groups. Participants were observed for incident TB and herpes zoster from diabetes diagnosis until treatment crossover or December 2013. Statin user and nonstatin user were the time-dependent variables in Cox regression analysis. RESULTS: Over 240 782 person-years of observation, statin users (n = 17 696) were associated with a lower TB risk than nonstatin users (n = 5327) and the drug-free group (n = 22 316) (adjusted hazard ratio [aHR]: 0.66; 95% confidence interval [CI]: 0.44-0.99 and aHR: 0.57; 95% CI: 0.44-0.73). Compared with nonstatin users, statin users showed a dose-dependent association with TB risk (low-potency statin users, aHR: 0.692; 95% CI: 0.455-1.053; high-potency users, aHR: 0.491; 95% CI: 0.241-0.999). Statin users presented with a higher risk of herpes zoster than nonstatin users and the drug-free group (aHR: 1.23; 95% CI: 1.01-1.50 and aHR: 1.20; 95% CI: 1.09-1.33). The risks of TB and herpes zoster were not statistically different between nonstatin users and the drug-free group. CONCLUSION: Compared with nonstatin drugs, statin use was specifically associated with a decreased risk of TB but a moderately increased risk of herpes zoster in this cohort study.
It remains uncertain whether statin use is associated with the risks of tuberculosis (TB) and herpes zoster in patients with type 2 diabetes. This study aims to assess the effects of statins vs nonstatin lipid-lowering agents on the risk of these infectious diseases in patients with diabetes. METHODS:Participants in the Taiwan National Health Insurance Research Database diagnosed with type 2 diabetes in 2001-2013 were classified as statin users, nonstatin users and lipid-lowering drug-free groups. Participants were observed for incident TB and herpes zoster from diabetes diagnosis until treatment crossover or December 2013. Statin user and nonstatin user were the time-dependent variables in Cox regression analysis. RESULTS: Over 240 782 person-years of observation, statin users (n = 17 696) were associated with a lower TB risk than nonstatin users (n = 5327) and the drug-free group (n = 22 316) (adjusted hazard ratio [aHR]: 0.66; 95% confidence interval [CI]: 0.44-0.99 and aHR: 0.57; 95% CI: 0.44-0.73). Compared with nonstatin users, statin users showed a dose-dependent association with TB risk (low-potency statin users, aHR: 0.692; 95% CI: 0.455-1.053; high-potency users, aHR: 0.491; 95% CI: 0.241-0.999). Statin users presented with a higher risk of herpes zoster than nonstatin users and the drug-free group (aHR: 1.23; 95% CI: 1.01-1.50 and aHR: 1.20; 95% CI: 1.09-1.33). The risks of TB and herpes zoster were not statistically different between nonstatin users and the drug-free group. CONCLUSION: Compared with nonstatin drugs, statin use was specifically associated with a decreased risk of TB but a moderately increased risk of herpes zoster in this cohort study.
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Y A Kang; N-K Choi; J-M Seong; E Y Heo; B K Koo; S-S Hwang; B-J Park; J-J Yim; C-H Lee Journal: Int J Tuberc Lung Dis Date: 2014-06 Impact factor: 2.373
Authors: Joseph A Salami; Haider J Warraich; Javier Valero-Elizondo; Erica S Spatz; Nihar R Desai; Jamal S Rana; Salim S Virani; Ron Blankstein; Amit Khera; Michael J Blaha; Roger S Blumenthal; Barry T Katzen; Donald Lloyd-Jones; Harlan M Krumholz; Khurram Nasir Journal: J Am Heart Assoc Date: 2018-01-22 Impact factor: 5.501
Authors: Juan M Cubillos-Angulo; Betânia M F Nogueira; María B Arriaga; Beatriz Barreto-Duarte; Mariana Araújo-Pereira; Catarina D Fernandes; Caian L Vinhaes; Klauss Villalva-Serra; Vanessa M Nunes; João P Miguez-Pinto; Eduardo P Amaral; Bruno B Andrade Journal: Front Med (Lausanne) Date: 2022-09-23